KIT Mutations in AML by Fragment Analysis and Sequencing
2002437
Ordering Recommendation
Prognostication in core-binding factor-related (CBF) AML.
Submit With Order
Mnemonic
KIT AML
Methodology
Polymerase Chain Reaction/Fragment Analysis/Sequencing
Performed
DNA isolation: Sun-Sat
Assay:
Sun, Tue, Thu
Reported
12-14 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) or pink (K2EDTA). OR bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood (Min: 1 mL) OR 3 mL bone marrow (Min: 1 mL).  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemoloyzed specimens.  
Remarks
 
Stability
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note
CPT Code(s)
81404
Components
Component Test Code*Component Chart Name
2002439Kit Mutations in AML
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • CBF AML testing
  • CKIT
  • Exon 8 and 17
  • GST8
  • KIT ex 8
  • KIT exon 8